Abstract
Background The WHO Neglected Tropical Disease Roadmap update for 2021–2030 includes new goals of elimination of schistosomiasis as a public health problem in all endemic countries. Despite heightened efforts since 2012, critical action is still required in addressing barriers to Mass Drug Administration, the primary method of control. This includes improvement in adherence by the populations in persistent schistosomiasis hotspots. One such hotspot is the shoreline of Lake Albert, Uganda, where schistosomiasis control is provided to school-aged children and adults. An overemphasis on regular treatment, without comprehensively addressing factors that result in low uptake of treatment in these high-risk populations is likely to impact the elimination of schistosomiasis as a public health problem.
Methods An ethnographic study using in-depth interviews, key informant interviews, focus group discussions and participant observation was conducted in two study sites along Lake Albert. Thematic content analysis was used during data analysis.
Results The study revealed that the size, taste and smell of the drug, along with its side-effects; poor community integration and occupational behaviour resulting in non-mobilisation; and unfounded rumours and beliefs remain reasons for persistent low uptake of praziquantel by some. Conversely, lived experience of improved health through participation and knowledge of the dangers of the disease if not treated, facilitated treatment uptake. Social influence in crucial knowledge attainment was clear through positive attitudes to localised sensitisation by community drug distributors, along with the delivery of the drug at no cost at home. Crucially, for the majority of participants the facilitating factors were found to outweigh the inhibitory factors related to the drug’s side effects.
Conclusion We recommend a good community engagement strategy that provides continuous education and sensitisation, with improved recruitment and training provision for Community Drug Distributors to facilitate programme reach to groups with current poor engagement.
Author summary Over the last two decades, in the Lake Albert region, Uganda, there has been a number of interventions targeted at schistosomiasis by grass root structures, and district and national level actors; but despite this the Lake Albertine districts remain a highly endemic region for schistosomiasis. In recognition of this persistent schistosomiasis, we examined the factors that inhibit or facilitate adherence to mass drug administration (MDA) using an ethnographic approach. Lived experience of improved health through participation and knowledge of the dangers of the disease if not treated, facilitated treatment uptake. Localised social influence was crucial in gaining knowledge that facilitated uptake. Key were positive attitudes to sensitisation conducted by community drug distributors; whilst uptake of treatment by children was reportedly heavily influenced by their mothers’ positive attitudes to treatment. The drug itself, praziquantel, was described as “very strong” and “effective” because of the relief from symptoms. There are, however, a number of people, both children and adults, who fail to adhere to MDA. Therefore, we recommend continuous education and sensitisation, alongside increased number and training of Community drug distributors/village health team members; with continued motivation for them as they are vital in enabling treatment uptake.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the FibroScHot project which is part of the EDCTP2 programme supported by the European Union (RIA2017NIM-1842-FibroScHot)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
School of Social Sciences Research Ethics committee of Makerere University gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study will be publicly available from UK Data Service ReShare with the identifier(s) [857010]